FoundationOne Liquid is the first and only liquid biopsy test to show prospective clinical utility in a global, registrational trial for patients with newly diagnosed, metastatic non-small cell lung cancer (NSCLC).1

Genomic Testing

FOUNDATIONONE®LIQUID

FoundationOne Liquid is our next-generation liquid biopsy test for solid tumors utilizing circulating tumor DNA (ctDNA).
  • Cancer Type
    Solid Tumor
  • Sample Type
    Peripheral Whole Blood
  • Results Expected
    <2 weeks*

What is FoundationOne Liquid?

FoundationOne Liquid may help inform cancer care from a simple blood draw.

This liquid biopsy test provides targeted gene and microsatellite instability-high (MSI-H) results2 that may help inform therapy selection and clinical trial options for advanced-stage cancer patients using a minimally invasive sample type. By analyzing ctDNA with our comprehensive genomic profiling approach and providing expertly curated reports, FoundationOne Liquid empowers providers to make more informed clinical decisions.

FoundationOne Liquid is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine.3

Providers: Order a Kit

Overview

FoundationOne Liquid

  • 70

    genes interrogated

  • 99%

    PPV⁴

  • 99%

    sensitivity⁵

  1. FoundationOne Liquid is the only liquid biopsy test that has demonstrated the ability to identify patients with ALK fusions in a global prospective trial for metastatic NSCLC at similar frequencies historically published with tissue testing.6
  2. Includes MSI-H status and guideline-recommended genes to help inform therapy selection and identify clinical trial options for patients with solid tumors.
  3. Requires only two 8.5mL tubes of blood

Please see footnotes below for information on PPV and sensitivity

Order FoundationOne Liquid

We make it easy for providers to order a kit for FoundationOne Liquid. When you’re ready to order a test, see the Provider Resources below.

Order a Kit

A doctor looking at the camera

Providers

FoundationOne Liquid is available through the online portal link below or by fax using our downloadable test requisition form. We have also provided additional PDF resources for those who want to learn more before ordering.

Order a Test

Patients

FoundationOne Liquid is ordered by your healthcare provider and we offer financial assistance for those who qualify. Download our form or apply online and speak with your healthcare provider today.

Apply Now

Questions? We’re here to help.

Call Foundation Medicine Client Services at (888) 988-3639 between 8:00 am ET and 8:00 pm ET, Monday through Friday. You can also send us an email and a representative will respond during regular business hours.

Contact Us

We have even more to offer.

Learn more about our other tests, FoundationOne®CDx, FoundationOne®Heme, or explore insights and trials or partnerships.

* Typical turnaround time from receipt of specimen is two weeks

1 LBA81_PR ‘Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: initial results from ALK+ cohort’ will be presented by Shirish Gadgeel during the proffered paper session on Monday, 30 September 2019, 08:30-10:00 CEST in Madrid Auditorium (Hall 2). Annals of Oncology, Volume 30, Supplement 5, October 2019.

2 MSI status will be reported for samples determined to have high microsatellite instability.

3 FoundationOne Liquid has not been cleared or approved by the U.S. Food and Drug Administration. For more information on our laboratory developed tests (LDTs) please see the Technical Specifications at  www.foundationmedicine.com.

4 >99% PPV for all alterations, calculated as a weighted average of the PPV for each class of alteration, with the weighting based upon the frequency with which FoundationOne Liquid detects each class of alteration. The PPV for base substitutions, indels and rearrangements is >99% at >0.5% MAF. The PPV for copy number variations at ≥20% tumor fraction is 97.6%.Internal data on file.

5 >99% sensitivity for base substitutions, indels and rearrangements at >0.5% MAF. Sensitivity for copy number variations is >95% when the tumor fraction is ≥20%. Internal data on file.

6 Dearden et al. Ann Oncol. 2013 Sep; 24(9): 2371–2376.